Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2018 Mar-2017 Mar-2016 Mar-2015
Growth matrix (%)        
Revenue growth 15 8.81 (4.10) --
Op profit growth 53.50 27 (36) --
EBIT growth 55.50 24.40 (34) --
Net profit growth 41.90 21.30 (34) --
Profitability ratios (%)        
OPM 31.70 23.70 20.40 30.60
EBIT margin 32 23.70 20.70 30
Net profit margin 19.80 16 14.40 20.90
RoCE 24.40 17.10 14.70 --
RoNW 4.31 3.45 3.11 --
RoA 3.78 2.90 2.55 --
Per share ratios ()        
EPS 9.72 6.85 5.64 8.54
Dividend per share 1.50 1 2 0.60
Cash EPS 8.04 5.17 4.27 7.62
Book value per share 60.30 52.40 46.80 43.90
Valuation ratios        
P/E 17.30 24.20 34.20 33.80
P/CEPS 20.90 32.10 45.20 37.80
P/B 2.78 3.16 4.12 6.56
EV/EBIDTA 9.67 14.50 19 20.80
Payout (%)        
Dividend payout 18.60 17.60 44.80 8.45
Tax payout (37) (29) (26) (28)
Liquidity ratios        
Debtor days 31.30 33.40 34.20 --
Inventory days 67.70 59.10 60.40 --
Creditor days (42) (35) (43) --
Leverage ratios        
Interest coverage (43) (23) (18) (33)
Net debt / equity 0.01 0.09 (0.30) (0.30)
Net debt / op. profit 0.03 0.48 (1.60) (1.10)
Cost breakup ()        
Material costs (25) (28) (33) (35)
Employee costs (9.80) (9.60) (8.20) (7)
Other costs (34) (39) (38) (28)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2018 Mar-2017 Mar-2016 Mar-2015
Revenue 625 544 500 521
yoy growth (%) 15 8.81 (4.10) --
Raw materials (154) (152) (166) (181)
As % of sales 24.60 27.90 33.30 34.70
Employee costs (61) (52) (41) (37)
As % of sales 9.80 9.60 8.20 7.01
Other costs (212) (210) (191) (144)
As % of sales 33.90 38.70 38.10 27.70
Operating profit 198 129 102 159
OPM 31.70 23.70 20.40 30.60
Depreciation (21) (21) (17) (12)
Interest expense (4.60) (5.70) (5.90) (4.70)
Other income 23.30 21.10 19.30 8.58
Profit before tax 196 123 97.60 152
Taxes (72) (36) (26) (43)
Tax rate (37) (29) (26) (28)
Minorities and other -- -- -- --
Adj. profit 124 87.20 71.80 109
Exceptional items -- -- -- --
Net profit 124 87.20 71.80 109
yoy growth (%) 41.90 21.30 (34) --
NPM 19.80 16 14.40 20.90
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2018 Mar-2017 Mar-2016 Mar-2015
Profit before tax 196 123 97.60 152
Depreciation (21) (21) (17) (12)
Tax paid (72) (36) (26) (43)
Working capital (204) (241) 241 --
Other operating items -- -- -- --
Operating cashflow (101) (175) 295 --
Capital expenditure 85.20 23.80 (24) --
Free cash flow (16) (151) 271 --
Equity raised 1,197 1,162 1,190 --
Investments 279 301 (301) --
Debt financing/disposal (66) (2.60) 18.30 --
Dividends paid 19.10 12.70 25.50 7.64
Other items -- -- -- --
Net in cash 1,412 1,322 1,205 --
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2018 Mar-2017 Mar-2016 Mar-2015
Equity capital 12.70 12.70 12.70 12.70
Preference capital -- -- -- --
Reserves 755 654 583 547
Net worth 767 667 595 559
Minority interest
Debt 27.50 70.80 82.60 109
Deferred tax liabilities (net) 56.40 48.40 38.80 25.50
Total liabilities 851 786 717 693
Fixed assets 332 315 313 279
Intangible assets
Investments 279 301 0.12 0.04
Deferred tax asset (net) 33.10 50.30 43.80 2.74
Net working capital 186 110 119 132
Inventories 139 92.50 83.50 81.80
Inventory Days 81.40 62.10 61 57.30
Sundry debtors 61.50 45.80 53.60 40.20
Debtor days 35.90 30.80 39.10 28.10
Other current assets 80.40 49.90 55.40 92.50
Sundry creditors (59) (40) (40) (53)
Creditor days 34.20 26.70 29.30 37.30
Other current liabilities (37) (38) (34) (29)
Cash 20.80 9.17 241 280
Total assets 851 786 717 693
Switch to
Consolidated
Standalone


Suven Life Sciences Ltd Report not showing data